Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA7 | P43166 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4185933 | 1.00 | CA1 (0.51) | CA1CA2CA7CA9TSHR | |
| SCHEMBL9068544 | 1.00 | CA1 (0.51) | CA1CA2CA7CA9TSHR | |
| SCHEMBL25435936 | 0.96 | CA1 (0.49) | CA1CA2CA7CA9TSHR | |
| SCHEMBL11315619 | 0.89 | CA1 (0.49) | CA1CA2CA7CA9TSHR | |
| SCHEMBL11302178 | 0.89 | CA1 (0.49) | CA1CA2CA7CA9TSHR | |
| SCHEMBL15519785 | 0.88 | CA1 (0.47) | CA1CA2CA7CA9TSHR | |
| SCHEMBL11177231 | 0.88 | CA1 (0.47) | CA1CA2CA7CA9TSHR | |
| SCHEMBL9592045 | 0.87 | CA1 (0.50) | CA1CA2CA7CA9TSHR | |
| SCHEMBL9188557 | 0.85 | CA1 (0.66) | CA1CA2CA7CA9TSHR | |
| SCHEMBL9187215 | 0.85 | CA1 (0.66) | CA1CA2CA7CA9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053605-A1 | DENTAL PORCELAIN PASTE, DENTAL PORCELAIN KIT, AND METHOD FOR PRODUCING DENTAL PORCELAIN PROSTHESIS | KURARAY NORITAKE DENTAL INC. (JP) | 2026-02-26 | — | — | US | disclosed |
| US-20260027016-A1 | PORCELAIN PASTE FOR DENTISTRY | KURARAY NORITAKE DENTAL INC. (JP) | 2026-01-29 | — | — | US | disclosed |
| EP-4582073-A1 | DENTAL PORCELAIN PASTE, DENTAL PORCELAIN KIT, AND METHOD FOR PRODUCING DENTAL PORCELAIN PROSTHESIS | Kuraray Noritake Dental Inc. (JP) | 2025-07-09 | — | — | EP | disclosed |
| EP-4563138-A1 | PORCELAIN PASTE FOR DENTISTRY | Kuraray Noritake Dental Inc. (JP) | 2025-06-04 | — | — | EP | disclosed |
| CN-119816284-A | Dental porcelain paste, dental porcelain kit, and method for producing dental porcelain patch | 可乐丽则武齿科株式会社 | 2025-04-11 | — | — | CN | disclosed |
| CN-119604265-A | Porcelain paste for dentistry | 可乐丽则武齿科株式会社 | 2025-03-11 | — | — | CN | disclosed |
| CN-114773160-B | 1, 3-Aliphatic diol compound and derivative thereof | 基因组股份公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119320236-A | Ceramic paste for glazing | 爱迪特（秦皇岛）科技股份有限公司 | 2025-01-17 | — | — | CN | disclosed |
| WO-2024048794-A1 | DENTAL PORCELAIN PASTE, DENTAL PORCELAIN KIT, AND METHOD FOR PRODUCING DENTAL PORCELAIN PROSTHESIS | クラレノリタケデンタル株式会社 | 2024-03-07 | — | — | WO | disclosed |
| WO-2024024661-A1 | PORCELAIN PASTE FOR DENTISTRY | クラレノリタケデンタル株式会社 | 2024-02-01 | — | — | WO | disclosed |
| US-20180072645-A1 | 1,3-FATTY DIOL COMPOUNDS AND DERIVATIVES THEREOF | REG LIFE SCIENCES LLC (US) | 2018-03-15 | — | — | US | disclosed |
| WO-2017214024-A1 | SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20170348422-A1 | SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2017-12-07 | — | — | US | disclosed |
| EP-1061062-B1 | PROCESS FOR PRODUCING BUTANETRIOL DERIVATIVES | DAISO CO LTD (JP) | 2009-02-18 | — | — | EP | disclosed |
| US-20040024261-A1 | Process for preparing butanetriol derivative | DAISO CO., LTD. (JP) | 2004-02-05 | — | — | US | disclosed |
| US-6620977-B1 | Reacting 1,2,4-butanetriol in multiple steps with specified reagents using selective protection and deprotection of hydroxyl groups | DAISO CO., LTD. (JP) | 2003-09-16 | — | — | US | disclosed |
| EP-1061062-A1 | PROCESS FOR PRODUCING BUTANETRIOL DERIVATIVE | DAISO CO., LTD. (JP) | 2000-12-20 | — | — | EP | disclosed |
| US-5530143-A | REDUCTION OF (3S)-3-HYDROXYOCTANEDIOIC DIESTER WITH COMPLEX HYDRIDE | BASF AKTIENGESELLSCHAFT (DE) | 1996-06-25 | — | — | US | disclosed |
| EP-0487986-B1 | Process for the preparation of esters of (6s)-6,8-dihydroxyoctanoic acid | BASF AG (DE) | 1995-06-21 | — | — | EP | disclosed |
| EP-0487986-A2 | Process for the preparation of esters of (6s)-6,8-dihydroxyoctanoic acid | BASF Aktiengesellschaft (DE) | 1992-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348422-A1 | SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | SHBG, EPCAM, ITGAV | CA1 1480/4885CA2 3109/4885CA7 2226/4885 |
| US-20260027016-A1 | PORCELAIN PASTE FOR DENTISTRY | NUP205, SMARCC1, NUP50 | CA1 179/4885CA2 413/4885CA7 445/4885 |
| US-20260053605-A1 | DENTAL PORCELAIN PASTE, DENTAL PORCELAIN KIT, AND METHOD FOR PRODUCING DENTAL PORCELAIN PROSTHESIS | GLA, LBR, PGA5 | CA1 17/4885CA2 165/4885CA7 9/4885 |
| US-20180072645-A1 | 1,3-FATTY DIOL COMPOUNDS AND DERIVATIVES THEREOF | DGAT1, DGAT2, DSG1 | CA1 4200/4885CA2 4285/4885CA7 3666/4885 |
| US-20040024261-A1 | Process for preparing butanetriol derivative | CYP4B1, CYP11B2, CYP11B1 | CA1 3367/4885CA2 4174/4885CA7 1754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.